Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

MedCAC meets on Bayesian methods

This article was originally published in The Gray Sheet

Executive Summary

Medicare Evidence Development & Coverage Advisory Committee (MedCAC) will meet June 17 at CMS headquarters in Baltimore to discuss the application of Bayesian statistical analysis methods to the development of evidence for coverage decisions. The meeting will introduce Bayesian concepts, compare Bayesian and frequentist statistical approaches, and provide case examples of Bayesian meta-analyses. CMS recently released a 1technology assessment, titled "Use of Bayesian Techniques in Randomized Clinical Trials: A CMS Case Study." The document provides a basic tutorial on Bayesian statistics and a summary of published research on how Bayesian techniques "can modify inferences that affect policy-level decision making." FDA issued a 2draft guidance on Bayesian analysis in clinical trials in 2006

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

MT027550

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel